MEDTECH

FDA Grants ILiAD Biotechnologies Fast Track Designation for Next Generation Pertussis Vaccine BPZE1

ILiAD Biotechnologies | January 04, 2022

ILiAD Biotechnologies, a late stage biotech development company focused on global eradication of disease due to Bordetella pertussis, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BPZE1, a next generation vaccine for active booster immunization against pertussis.

BPZE1 is the most advanced next generation pertussis vaccine currently in clinical development. Developed in the laboratory of Camille Locht, PhD, at the Institut Pasteur de Lille and French National Institute of Health and Medical research BPZE1 is a live-attenuated intranasal vaccine designed to overcome deficiencies of current pertussis vaccines, including poor durability of protection and failure to prevent nasopharyngeal Bordetella pertussis infections that lead to escape mutants and transmission to vulnerable infants. Four clinical trials studying BPZE1 in healthy adults have been completed to date, including positive topline results from a 300-participant adult Phase 2b trial demonstrating that BPZE1 induced durable mucosal immunity and reduced nasal colonization — two key factors necessary for the prevention of transmission and reduction of epidemic pertussis cycles. Earlier this month, the Company also announced initiation and enrollment of the first participants in the BPZE1 SUPER Trial (Standing Up to PERtussis) – the fifth clinical BPZE1 study and the first study in school-age children.

Section 506(b) of the FD&C Act provides for the designation of a drug as a Fast Track product “…if it is intended, whether alone or in combination with one or more other drugs, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition.” Fast Track provides opportunities for frequent Company interactions with the FDA and the potential for accelerated approval and priority review.

We are pleased that the FDA is aligned with ILiAD’s position that there is an unmet clinical need for a more effective pertussis vaccine and that the evidence to date supports the potential for BPZE1 to address the major gaps in protection against pertussis. We look forward to continuing to work with the FDA and other global Regulatory Agencies to further clinical development of BPZE1 and to safely and efficiently bring BPZE1 to US and global markets.”

 Dr. Keith Rubin, Chief Executive Officer of ILiAD. Dr. Rubin

About Pertussis
Pertussis is a life-threatening disease caused by the highly contagious respiratory bacterium Bordetella pertussis. According to U.S. Centers for Disease Control and Prevention, each year pertussis affects approximately 16 million people globally, accounting for nearly 200,000 deaths. Although estimated global vaccination coverage is 84%, current vaccines have failed to control epidemics. In addition, current vaccines do not fully protect infants under age 6 months, since immunization requires multiple injections, usually at 2, 4 and 6 months.

About BPZE1
BPZE1 is a next-generation live-attenuated pertussis vaccine designed to induce comprehensive and durable protection against B. pertussis infection and disease. BPZE1 is being developed to block B. pertussis from colonizing adult and adolescent nasal passages, to protect adults and adolescents from whooping cough, and to potentially prevent transmission, including transmission to infants. While ILiAD is currently focused on developing a vaccine to directly protect adults and adolescents and to indirectly protect vulnerable infants, future development aims to immunize neonates directly.

About Fast Track Designation
Fast Track Designation by the U.S. FDA is a process designed to facilitate the development and expedite the review of investigational products to treat serious conditions and fill an unmet medical need, with the intent of getting important new products to the population in an expedited manner. Specifically, Fast Track Designation provides the option of licensure via the accelerated approval pathway, which allows licensure based on surrogate endpoints. Additionally, Fast Track designation facilitates meetings with the FDA to discuss all aspects of development to support licensure and provides the opportunity to submit sections of a BLA on a rolling basis as data become available. This permits the FDA to review modules of the BLA as they are received instead of waiting for the entire BLA submission. Priority review is an additional benefit that may potentially be available for BPZE1 as part of the Fast Track designation.

About ILiAD Biotechnologies, LLC
ILiAD Biotechnologies is a privately held, clinical stage biotechnology company dedicated to the prevention and treatment of human disease caused by Bordetella pertussis. The company is developing and acquiring key technologies, working with leading scientists to overcome the limitations of current vaccines, investigating the impact of B. pertussis in a range of human disease, and is focused on validating its proprietary vaccines in human clinical trials.

Spotlight

Delivering drugs to their site of action is a necessary feature of all medications. Different strategies are currently being employed to enable the targeted delivery of biotherapeutics. This infographic highlights the latest therapeutic delivery applications, describing: how antibody-drug conjugates target and kill tumor cells the challenges to antibody-drug conjugate commercial-scale manufacture nanoparticle therapeutics and the array of nanoparticles that exist a time of implementation in modern medicine a look to the future and the DNA slingshot!

Spotlight

Delivering drugs to their site of action is a necessary feature of all medications. Different strategies are currently being employed to enable the targeted delivery of biotherapeutics. This infographic highlights the latest therapeutic delivery applications, describing: how antibody-drug conjugates target and kill tumor cells the challenges to antibody-drug conjugate commercial-scale manufacture nanoparticle therapeutics and the array of nanoparticles that exist a time of implementation in modern medicine a look to the future and the DNA slingshot!

Related News

MEDICAL

Slate Bio Announces the Launch with Seed Financing to Develop Next Generation IL-2 Therapies

Slate Bio | January 20, 2021

Slate Bio, Inc., reports the closing of a $1.75 million venture financing. Epidarex Capital drove the speculation round with cooperation from the UVA Licensing and Ventures Group Seed Fund, Center for Innovative Technology's GAP BioLife Fund, VTC Seed Fund, PharmaDirections, Inc., the board and others. Record is a pre-clinical biotechnology organization creating outlook changing IL-2 mixes dependent on examination directed at the University of Virginia School of Medicine. IL233, Slate's lead candidate, is a first in class drug that initiates constant abatement in animal models of autoimmune and inflammatory diseases. Slate's IL233 is a bifunctional IL-2 combination cytokine that increases Regulatory T cells (Tregs) and tissue resident Tregs for autoimmune and provocative infections. IL233 joins the de-gambling certainty of IL-2 and the collaboration and toughness of IL-33. IL233 goes about as a pharmacological kick off to revive the body's inherent pathways to stop inflammation, end mal-adaptive repair and promote regeneration of damaged tissues to restore homeostasis.

Read More

CELL AND GENE THERAPY

AgeX Therapeutics Receives Stock Exchange Deficiency Letter

AgeX Therapeutics | November 24, 2021

AgeX Therapeutics , Inc. a biotechnology company developing therapeutics for human aging and regeneration, announced that on November 17, 2021 it received a letter from the staff of the NYSE American indicating that AgeX does not meet certain of the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide in that AgeX has stockholders equity of less than $2,000,000 and has incurred losses from continuing operations and/or net losses during its two most recent fiscal years, and that it has stockholders equity of less than $4,000,000 and has incurred losses from continuing operations and/or net losses during three out of four of its most recent fiscal years. Pursuant to Section 1009 of the Exchange Company Guide and as provided in the Deficiency Letter, AgeX may provide the Exchange staff with a plan (the "Plan") by December 17, 2021 advising the Exchange staff of action AgeX has taken and will take that would bring AgeX into compliance with the Exchange’s continued listing standards by June 17, 2023. AgeX intends to submit a Plan by the December 17, 2021 deadline. There is no assurance that the Exchange staff will accept the Plan. If the Exchange staff accepts the Plan, the Exchange staff will review AgeX’s compliance with the Plan on a quarterly basis and if AgeX does not show progress consistent with the Plan or is not in compliance with the Exchange’s continued listing standards by June 17, 2023, the Exchange will commence delisting procedures. If AgeX does not submit the Plan or if the Exchange staff does not accept the Plan, the Exchange staff will promptly initiate delisting proceedings. AgeX intends to make arrangements to have its common stock quoted on an electronic interdealer quotation system if its common stock is delisted from the Exchange. About AgeX Therapeutics AgeX Therapeutics, Inc. is focused on developing and commercializing innovative therapeutics to treat human diseases to increase healthspan and combat the effects of aging. AgeX’s PureStem® and UniverCyte™ manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX’s revolutionary longevity platform induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. HyStem® is AgeX’s delivery technology to stably engraft PureStem or other cell therapies in the body. AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.

Read More

CELL AND GENE THERAPY

Biocytogen Completes a New Round of Financing Totaling Tens of Millions of Dollars

Biocytogen | June 23, 2021

Biocytogen, a worldwide biotechnology organization zeroed in on neutralizer drug innovative work (R&D) utilizing creative genetically designed creature models, today declared the fruitful culmination of another round of financing adding up to a huge number of dollars. The financing was together finished by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was set up in 2009. Utilizing its primary quality altering innovation, the organization autonomously created mouse stages for completely human neutralizer disclosure, RenMab® and RenLite®, that have free protected innovation rights. With the execution of these stages, Biocytogen has advanced from an agreement research association (CRO) into a global biotechnology organization with aptitude crossing the whole cycle of new drug R&D, including immune response drug target check, high-throughput single B cell counter acting agent revelation innovation, in vivo drug viability assessment utilizing adapted objective mice, and clinical turn of events. Genetic engineering of RenMab® and RenLite® mice has empowered the integration of Biocytogen's innovative qualities into a one of a kind enormous scope R&D plan for the revelation of helpful antibodies, a drive named the RenMice HiTS Platform. The HiTS Platform means the organization's obligation to finish high-productivity counter acting agent revelation and in vivo drug viability screening of in excess of 1,000 neutralizer targets in the following not many years, zeroing in on the disclosure of first-in-class and top tier drug targets. Through the ID of immune response drives that have been confirmed for adequacy in creature models, Biocytogen has set up co-improvement associations with in excess of twelve biotechnology and pharmaceutical organizations.

Read More